Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Total Non-Current Liabilities (2022 - 2025)

Corvus Pharmaceuticals has reported Total Non-Current Liabilities over the past 4 years, most recently at $321000.0 for Q3 2025.

  • Quarterly results put Total Non-Current Liabilities at $321000.0 for Q3 2025, down 48.64% from a year ago — trailing twelve months through Sep 2025 was $321000.0 (down 48.64% YoY), and the annual figure for FY2024 was $593000.0, down 8.49%.
  • Total Non-Current Liabilities for Q3 2025 was $321000.0 at Corvus Pharmaceuticals, down from $414000.0 in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for CRVS hit a ceiling of $1.0 million in Q2 2022 and a floor of $321000.0 in Q3 2025.
  • Median Total Non-Current Liabilities over the past 4 years was $636500.0 (2023), compared with a mean of $681857.1.
  • Biggest five-year swings in Total Non-Current Liabilities: dropped 8.49% in 2024 and later tumbled 48.64% in 2025.
  • Corvus Pharmaceuticals' Total Non-Current Liabilities stood at $985000.0 in 2022, then plummeted by 34.21% to $648000.0 in 2023, then decreased by 8.49% to $593000.0 in 2024, then crashed by 45.87% to $321000.0 in 2025.
  • The last three reported values for Total Non-Current Liabilities were $321000.0 (Q3 2025), $414000.0 (Q2 2025), and $503000.0 (Q1 2025) per Business Quant data.